Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAC-GA for Borderline Resectable Pancreatic Cancer
NCT02926183Phase 2Unknown
- Sponsor
- Wakayama Medical University
- Start
- Oct 2016
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel in pancreatic ductal adenocarcinoma (PDAC), sponsored by Wakayama Medical University. Primary endpoint: Overall Survival up to 60 months. Status: unknown.
02
Drugs
paclitaxel
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02926183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02926183.